PBESProceedings of Business and Economic Studies2209-26412209-265XBio-Byword Scientific Publishing Pty. Ltd.10.26689/pbes.v8i3.11162ArticleThe Management Practice and Reflection of Centralized Drug Procurement in Hospitalshttps://artdesignp.com/journal/PBES/8/3/10.26689/pbes.v8i3.11162LiYuchen2025832025-07-14The centralized procurement of drugs in the medical system is a key link, which not only affects the economic effect of institutions, but also relates to the medical quality and patient safety. In the current era, centralized drug procurement in hospitals can meet the needs of most patients; however, the specific steps of the work still need to be optimized. Starting from the level of hospital drug centralized procurement work, this paper discusses the policy background, analyzes the practice of drug centralized procurement in tertiary hospitals, and provides specific work management suggestions, aiming to improve work efficiency and serve as a reference for optimizing subsequent hospital drug centralized procurement work.

Lin L, Peng X, Tang R, et al., 2023, The Impact of the National Centralized Drug Procurement Policy on the Economic Accessibility of Drugs and the Structure of Hospital Drug Use. China Pharmacy, 34(24): 2968–2974.

Cui K, Li Z, Zhao Y, et al., 2023, The Impact of the Centralized Procurement Policy on the Use of Non-small Cell Lung Cancer Treatment Drugs in a Tertiary Cancer Hospital. China Pharmacy, 34(16): 1926–1930.

Chen Y, Deng Z, Gu H, et al., 2023, Analysis of the Characteristics and Safety of the Use of National Centralized Procurement-related Drugs in a Tertiary Hospital. Pharmacy Today, 33(7): 555–560.

Jin X, Wu L, Wang Y, et al., 2023, Analysis of the Impact of the National Centralized Procurement Drug Policy on the Use of Proton Pump Inhibitors in a Tertiary Hospital in Hefei. Anhui Medical Journal, 44(7): 863–868.

Peng L, Liu W, 2023, The Impact of Centralized Volume-based Procurement Management of Hospital Drugs on the Efficiency and Economy of Procurement. Journal of Aerospace Medicine, 34(5): 591–593.

Li M, Ling T, Shen W, et al., 2023, The Application of PDCA Cycle in the Management System of National Centralized Procurement Drugs in a Tertiary Hospital. Practical Pharmacy and Clinical Remedies, 26(5): 477–480.

Zeng Y, 2023, Analysis of the Application Effect of the National Centralized Drug Procurement and Use in Our Hospital. Journal of North Pharmacy, 20(5): 62–64.

Zeng X, 2023, Discussion on How to Control the Cost of Drugs and Health Materials — Taking X Tertiary Public Hospital as an Example. Accountant, (8): 98–100.

Liu Y, Ma Y, Cai L, et al., 2022, Practical Analysis of the Collaborative Management of National Centralized Procurement and Medical Insurance Negotiation Drugs — Taking a Tertiary Hospital in Beijing as an Example. China Health Insurance, (12): 17–22.

Li J, Zhao L, Chen W, et al., 2022, Management Practice and Thoughts on the Centralized Drug Procurement Work in Hospitals: Taking a Tertiary Hospital in Jilin Province as an Example. China Health Insurance, (11): 99–101.

Huang L, Hu B, 2022, Empirical Analysis of Drug Supply in Public Hospitals and Chain Drugstores under the Background of Centralized Procurement: Taking Statins as an Example. China Journal of Pharmaceutical Economics, 17(8): 67–70.

Zhang Q, Li L, Wang L, et al., 2022, Research on the Supply Guarantee of Drugs in the Pharmacy Department of Hospitals under the “4 + 7” Centralized Procurement New Policy. Journal of Clinical Rational Drug Use, 15(19): 163–165.

Xiao P, Tian D, 2022, Implementation Situation and Suggestions of Centralized Drug Procurement in Public Hospitals: Taking a Tertiary Hospital in Hubei Province as an Example. China Health Insurance, (4): 33–36.

Jiang Y, Tan Z, 2022, The Implementation Effect of China’s Drug Volume-based Procurement Policy and Its Optimization Suggestions. Chinese Health Service Management, 39(04): 287–291.

Yuan C, Li Y, Hao D, 2022, The Current Situation and Research of Medical Insurance Prepayment for Volume-based Procurement Drugs and Near-Zero-Profit Sales in Hospitals and Pharmacists’ Prescription Review. Journal of China Prescription Drug, 20(3): 58–59.